88398-53-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-4-sulfonamide,1,3-dimethyl-(9CI) is used as an active pharmaceutical ingredient for the development of new antimicrobial agents. Its antibacterial and antifungal properties make it a promising candidate for treating infections caused by resistant bacteria and fungi.
Used in Agrochemical Industry:
In the agrochemical industry, 1H-Pyrazole-4-sulfonamide,1,3-dimethyl-(9CI) is used as a component in the formulation of pesticides and fungicides. Its antimicrobial properties can help protect crops from diseases and pests, thereby increasing agricultural productivity.
Used in Carbonic Anhydrase Inhibition:
1H-Pyrazole-4-sulfonamide,1,3-dimethyl-(9CI) is studied for its potential as a carbonic anhydrase inhibitor. This application could lead to the development of treatments for conditions such as glaucoma, epilepsy, and cancer, where carbonic anhydrase inhibition plays a crucial role in managing the disease.
Further research is ongoing to explore the full range of potential applications for 1H-Pyrazole-4-sulfonamide,1,3-dimethyl-(9CI) in the fields of medicine and agriculture, with the aim of discovering additional uses and enhancing its therapeutic and protective capabilities.

Upstream product

• 89501-93-9 1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 
• 694-48-4 1,3-dimethyl-1H-pyrazole 

Relevant academic research and scientific papers

PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The disclosure provides processes for preparing a compound of Formula (I).

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS

A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

NOVEL COMPOUNDS

The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.

Herbicidal diazoles sulfonamides

This invention relates to herbicidal heterocyclic aminocarbonyl diazole sulfonamides compounds, compositions thereof and a method for their use to control the growth of undesired vegetation.